Seegene Announces Submission to U.S. FDA for Emergency Use Authorization of Its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay

Published on: BUSINESS WIRE Real-time test differentiates influenza A & B, RSV and COVID-19 SEOUL, South Korea (March 1, 2021)— Seegene Inc., (KQ096530), a biotechnology company specializing in molecular diagnostics, has submitted its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay to the U.S. Food and Drug Administration for Emergency Use Authorization (EUA).  Seegene’s Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is a real-time […]

Seegene’s Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants

Published on: PR Newswire – Seegene’s new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 min– Seegene’s proprietary high multiplex technology enables detection of 10 different targets– S. Korean firm to research additional versions of variant diagnostic tests Seegene (KQ096530), a biotechnology company specializing in molecular diagnostics, said Wednesday it […]

Seegene’s saliva test for COVID-19 is just as effective as NPS test

Published on: PR Newswire A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen. A research team at the Department of Laboratory Medicine at Kangwon National University School of Medicine, led by Professor In-bum Suh, carried out the PCR test for COVID-19 on […]

Seegene introduces a High-throughput 8-plex Test for Flu A, Flu B, RSV and COVID-19 with dual internal controls

SEOUL, South Korea, Sept. 8, 2020 /PRNewswire/ — Seegene, Inc. introduced a single tube real-time RT-PCR assay, Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, which simultaneously detects and differentiates Flu A, Flu B, RSV A/B, and three different target genes of COVID-19 (S gene, RdRP gene and N gene). Given the similarity in terms of symptoms between seasonal flu and SARS-CoV-2, […]

Seegene’s Allplex™ 2019-nCoV Assay receives FDA Emergency Use Authorization

Published on: 매일경제 한국경제 PR Newswire 조선일보 SEOUL, Korea, Apr 22, 2020 – Seegene, Inc. announced that U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its Allplex™ 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2, the novel coronavirus responsible for the COVID-19 disease. Seegene’s Allplex 2019-nCoV Assay, already sold over 10 million tests globally […]

Seegene exported 10 Million COVID-19 Diagnostic Tests to Over 60 countries

Published on: PR Newswire ABC News Seegene, Inc., the leading multiplex diagnostic assay developer, today announced that the company has exported over 10 million tests of Allplex™ 2019-nCoV Assay to over 60 countries, which accounts for a significant portion of globally performed COVID-19 test numbers. Seegene’s proactive decision to develop COVID-19 test kit with the capability […]

Seegene Highlights Clinical Automated Nucleic Acid Extraction System at ASM Microbe 2019

2019 American Society for Microbiology Microbe Conference: Booth #1062 Published on: PR Newswire SEOUL, South Korea, June 21, 2019 /PRNewswire/ — Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered in South Korea, announced that it has completed the FDA registration of its nucleic acid extraction instrument, the Seegene STARlet, and will begin offering the clinical […]

Seegene launches a new anti-microbial drug resistance test kit, replacing the conventional culture method

Published on: PR Newswire SEOUL, South Korea, Nov. 26, 2018 /PRNewswire/ — Seegene Inc. (096530.KQ), a leading developer of multiplex PCR assays, announced that multi-site clinical trials for measuring clinical performance on screening the drug resistance of Enterobacteriaceae with the Allplex™ Entero-DR assay have been undergoing in 23 hospitals affiliated with the Italian Association for Clinical Microbiology (AMCLI). According […]

Seegene Unveils New Real-time PCR Analysis Technology, Drastically Increasing Its Multiplexing Capacity

Published on: PR Newswire SEOUL, South Korea, Sept. 19, 2018 /PRNewswire/ — Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced its proprietary technology, “MuCT™”. This is a real-time PCR based data acquiring and analyzing technology that increases its multiplexing capability per channel up to 5 Ct values, enabling it to run syndromic panel tests […]